Revvity: Strategic Acquisition in the Metabolism Segment Drives Stock Price to Multi-Year High!
Reading Time: 2 minutes
A hybrid model of systems and recurring services ensures earnings stability for the company. Through the acquisition of Human Cell Design, the company integrates specialized human cell models. This step into the future market propelled the stock to a multi-year high on September 15, 2026. Hybrid Model as the Basis for Stable Margins Revvity (RVTY) acts as a solution provider amid complex laboratory processes. The business model is not based on the sale of individual instruments but on a hybrid structure. Customers acquire coordinated...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
